Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.120
+0.070 (6.67%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Fate Therapeutics Revenue
In the year 2024, Fate Therapeutics had annual revenue of $13.63M, down -78.55%. Fate Therapeutics had revenue of $1.86M in the quarter ending December 31, 2024, with 10.98% growth.
Revenue (ttm)
$13.63M
Revenue Growth
-78.55%
P/S Ratio
9.26
Revenue / Employee
$75,309
Employees
181
Market Cap
127.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13.63M | -49.90M | -78.55% |
| Dec 31, 2023 | 63.53M | -32.77M | -34.03% |
| Dec 31, 2022 | 96.30M | 40.45M | 72.44% |
| Dec 31, 2021 | 55.85M | 24.41M | 77.66% |
| Dec 31, 2020 | 31.43M | 20.75M | 194.33% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
FATE News
- 4 days ago - Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) - GlobeNewsWire
- 16 days ago - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates - GlobeNewsWire
- 6 weeks ago - Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Fate Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap - Seeking Alpha
- 4 months ago - Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus - GlobeNewsWire
- 5 months ago - Fate Therapeutics Announces Leadership Transition - GlobeNewsWire